ACLARION, INC. Restricted Cash and Cash Equivalents
ACLARION, INC. (ACON) had Restricted Cash and Cash Equivalents of $171.45 thousand as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-11-14
- 2023-09-30: Restricted Cash and Cash Equivalents $171.45K.
- 2023-06-30: Restricted Cash and Cash Equivalents $614.52K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2023-09-30 | $171.45K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $614.52K 10-Q · filed 2023-08-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |